Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	210.95	120.24	69.57	9.46	3.22
Short-Term Investments	417.77	439.4	296.11	63.12	15.8
Cash & Cash Equivalents	628.72	559.63	365.68	72.58	19.02
Cash Growth	12.35%	53.04%	403.86%	281.63%	-
Receivables	5.9	1.01	0	0	0
Other Current Assets	3.33	2.52	1.45	1.39	0.04
Total Current Assets	637.95	563.16	367.13	73.97	19.05
Property, Plant & Equipment	107.8	110.66	9.06	3.98	2.36
Other Long-Term Assets	6.94	5.41	7.93	0.46	0.24
Total Long-Term Assets	114.74	116.06	17	4.45	2.59
Total Assets	752.69	679.22	384.12	78.41	21.65
Accounts Payable	6.64	2.42	7.08	0.04	2.41
Deferred Revenue	48.56	20.01	0	0	0
Other Current Liabilities	-18.19	12.66	14.95	7.28	1.14
Total Current Liabilities	37.01	35.1	22.02	7.32	3.55
Long-Term Debt	64.72	70.01	0	0	0
Other Long-Term Liabilities	51.47	23.18	4.75	9.85	12.17
Total Long-Term Liabilities	116.18	93.2	4.75	9.85	12.17
Total Liabilities	153.19	128.29	26.77	17.16	15.72
Total Debt	64.72	70.01	0	0	0
Debt Growth	-7.57%	-	-	-	-
Retained Earnings	-544.31	-344.24	-186.85	-66.54	-20.83
Comprehensive Income	0.27	-0.69	-0.23	0.01	0.01
Shareholders' Equity	599.5	550.93	357.35	-63.91	-19.55
Net Cash / Debt	564.01	489.62	365.68	72.58	19.02
Net Cash / Debt Growth	15.19%	33.89%	403.86%	281.63%	-
Net Cash Per Share	8.79	9.06	13.61	32.25	14.89
Working Capital	600.94	528.06	345.1	66.65	15.5
Book Value Per Share	9.34	10.20	13.30	-28.40	-15.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).